Home » Endo Files Response With FDA on Nebido Safety Questions
Endo Files Response With FDA on Nebido Safety Questions
Endo Pharmaceuticals said that the Food and Drug Administration has accepted for review its subsidiary’s complete response to safety questions the agency has raised about a new drug application for Nebido.
Philadelphia Business Journal
Philadelphia Business Journal
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May